Proteinuria and microalbuminuria in adults: Significance, evaluation, and treatment

被引：25

作者：

Venkat, KK ^{[1
]}

机构：

[1] Henry Ford Hosp, Dept Med, Div Nephrol, Detroit, MI 48202 USA

来源：

SOUTHERN MEDICAL JOURNAL | 2004年 / 97卷 / 10期

关键词：

angiotensin-converting enzyme inhibitors; angiotensin-receptor blockers; chronic kidney disease; microalbuminuria; proteinuria;

D O I：

10.1097/01.SMJ.0000140833.51533.46

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This paper reviews current concepts regarding the pathophysiology, diagnostic evaluation, and treatment of microalbuminuria and proteinuria in adults. Microalbuminuria (in diabetics) and proteinuria are early markers for potentially serious renal disease, and are associated with increased risk of atherosclerotic cardiovascular disease. Proteinuria also contributes to renal scarring, and accelerates the progression of chronic kidney disease to end-stage renal failure. Screening of diabetics for microalbuminuria, and the initial workup of proteinuria, should occur in the primary care setting. Reduction of microalbuminuria in diabetics may retard its progression to overt diabetic nephropathy. Therapy of renal diseases should aim for optimal blood pressure control and the maximum possible reduction in urinary protein excretion. Angiotensin-converting enzyme inhibitor (ACE-I) and/or angiotensin-receptor blocker (ARB) therapy is the most effective measure to achieve this. These drugs also provide protection against the cardiovascular problems that are highly prevalent in this patient population.

引用

页码：969 / 979

页数：11

共 92 条

[1] Nephrotoxicity of increased glomerular protein traffic [J].

Abbate, M ;

Benigni, A ;

Bertani, T ;

Remuzzi, G .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (02) :304-312

[2]

Abbate M, 1998, J AM SOC NEPHROL, V9, P1213

[3]

Agarwal R, 2001, KIDNEY INT, V59, P2282, DOI 10.1046/j.1523-1755.2001.0590062282.x

[4] Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].

Agodoa, LY ;

Appel, L ;

Bakris, GL ;

Beck, G ;

Bourgoignie, J ;

Briggs, JP ;

Charleston, J ;

Cheek, D ;

Cleveland, W ;

Douglas, JG ;

Douglas, M ;

Dowie, D ;

Faulkner, M ;

Gabriel, A ;

Gassman, J ;

Greene, T ;

Hall, Y ;

Hebert, L ;

Hiremath, L ;

Jamerson, K ;

Johnson, CJ ;

Kopple, J ;

Kusek, J ;

Lash, J ;

Lea, J ;

Lewis, JB ;

Lipkowitz, M ;

Massry, S ;

Middleton, J ;

Miller, ER ;

Norris, K ;

O'Connor, D ;

Ojo, A ;

Phillips, RA ;

Pogue, V ;

Rahman, M ;

Randall, OS ;

Rostand, S ;

Schulman, G ;

Smith, W ;

Thornley-Brown, D ;

Tisher, CC ;

Toto, RD ;

Wright, JT ;

Xu, SC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728

[5]

American Diabetes Association, 2003, DIABETES CARE S1, V26, pS94

[6]

APPEL BG, 2002, SYLLABUS, V1, P13

[7] Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine - Is this a cause for concern? [J].

Bakris, GL ;

Weir, MR .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) :685-693

[8]

Bakris GL, 2000, KIDNEY INT, V58, P2084, DOI 10.1046/j.1523-1755.2000.00381.x

[9] A practical approach to achieving recommended blood pressure goals in diabetic patients [J].

Bakris, GL .

ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (22) :2661-2667

[10]

BENNETT PH, 1995, AM J KIDNEY DIS, V25, P107

← 1 2 3 4 5 6 7 8 9 10 →